The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution's experience and a systematic review of the literature

Acta Neurochir (Wien). 2022 Nov;164(11):3011-3023. doi: 10.1007/s00701-022-05348-x. Epub 2022 Sep 19.


Introduction: Meningiomas account for over 30% of all primary brain tumors. While surgery can be curative for these tumors, several factors may lead to a higher likelihood of recurrence. For recurrent meningiomas, bevacizumab may be considered as a therapeutic agent, but literature regarding its efficacy is sparse. Thus, we present a systematic review of the literature and case series of patients from our institution with treatment-refractory meningiomas who received bevacizumab.

Methods: Patients at our institution who were diagnosed with recurrent meningioma between January 2000 and September 2020 and received bevacizumab monotherapy were included in this study. Bevacizumab duration and dosages were noted, as well as progression-free survival (PFS) after the first bevacizumab injection. A systematic review of the literature was also performed.

Results: Twenty-three patients at our institution with a median age of 55 years at initial diagnosis qualified for this study. When bevacizumab was administered, 2 patients had WHO grade I meningiomas, 10 patients had WHO grade II meningiomas, and 11 patients had WHO grade III meningiomas. Median PFS after the first bevacizumab injection was 7 months. Progression-free survival rate at 6 months was 57%. Two patients stopped bevacizumab due to hypertension and aphasia. Systematic review of the literature showed limited ability for bevacizumab to control tumor growth.

Conclusion: Bevacizumab is administered to patients with treatment-refractory meningiomas and, though its effectiveness is limited, outperforms other systemic therapies reported in the literature. Further studies are required to identify a successful patient profile for utilization of bevacizumab.

Keywords: Bevacizumab; Chemotherapy; Meningioma; Oncology; Recurrence; Skull base.

Publication types

  • Systematic Review

MeSH terms

  • Bevacizumab / therapeutic use
  • Humans
  • Meningeal Neoplasms* / surgery
  • Meningioma* / pathology
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Retrospective Studies


  • Bevacizumab